N33 Construction and Application of a Digital Management Platform for the Whole Course of Inflammatory Bowel Disease Patients Based on Action Research
Authors: Li S , Ma Y , Minfang L , Meijuan L , Yan C 
Published: January 2025

Abstract

Background
Utilize digital technology to construct a digital platform-based comprehensive management model for Inflammatory Bowel Disease (IBD) patients, and design and develop a digital management platform for IBD patients to achieve efficient, convenient, and intelligent IBD management.

Methods
From October 2021 to December 2022, under the guidance of action research methodology and based on the chronic disease care model, a digital platform-based management model for the entire course of Inflammatory Bowel Disease (IBD) patients was constructed through a spiral cycle process of "diagnosis, planning, implementation, evaluation, and reflection." Leveraging digital technology and using the online hospital as a vehicle, a comprehensive management platform for IBD patients throughout the entire course of their disease was designed and developed. A total of 83 IBD patients were selected and divided into a control group of 42 cases and an intervention group of 41 cases. The control group received outpatient follow-up plus standard treatment, while the intervention group received outpatient follow-up, standard treatment, and a digital comprehensive course management model. Each group was followed up for 3 and 6 months to observe the patients' fecal calprotectin levels, Inflammatory Bowel Disease Short Health Status (IBDSHS), and patient satisfaction.

Results
After two rounds of action research, a comprehensive management model for IBD patients throughout the entire course of their disease has been established, comprising three major elements: a digital platform, patients, and a healthcare management team. This platform offers services such as doctor-patient interaction, health consultation, self-management support, health data upload, access to laboratory test reports, and informational support. The intervention group showed lower fecal calprotectin levels at both 3 and 6 months compared to the control group; improvements in all dimensions of the brief health status were significantly greater in the intervention group, and satisfaction was higher in the intervention group than in the control group.

Conclusion
This study employs action research methods, integrating the practical aspects of IBD clinical diagnosis and care in China, the characteristics of IBD, patient needs, and medical staff requirements, to construct a digital platform-based management model for the entire course of IBD patients. This model not only aligns with the trend of innovative development in China's medical services but also establishes a closed-loop management model centered on IBD patients throughout the entire course of the disease, serving as a tool for the comprehensive management of IBD patients.

References
[1]Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. Lancet 2017;389:1741-1755.
[2]Yu Q, Zhu C, Feng S, et al. Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study. J Med Internet Res 2021;23:e20629.
[3]Johnson LC, Melmed GY, Nelson EC, Holthoff MM, Weaver SA, Morgan TS, Siegel CA. Fostering Collaboration Through Creation of an IBD Learning Health System. Am J Gastroenterol, 2017, 112(3):406-408.
[4]de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ.Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, random controlled trial. Lancet, 2017, 390(10098): 959-968.
[5]Yin AL, Hachuel D, Pollak JP, Scherl EJ, Estrin D. Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review. J Med Internet Res 2019, 21(8): e14630.
[6]Atreja A, Khan S, Rogers JD, Otobo E, Patel NP, Ullman T, et al. Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc 2015, 4(1): e23.